Revelation Partners

Revelation Partners, LLC is a private equity firm based in San Francisco, California, specializing in buyout and direct investments, including secondary investments. The firm primarily focuses on late-stage companies within the healthcare sector, targeting areas such as medical devices, biopharmaceuticals, healthcare information technology, and healthcare services. Revelation Partners aims to provide capital and liquidity to investors, companies, and funds, typically investing between $5 million and $30 million, with the capacity for larger transactions in collaboration with limited partners. The firm often seeks to acquire a majority stake in its investments and may also facilitate liquidity for existing investors through ownership purchases. Additionally, Revelation Partners is committed to supporting follow-on investments in its portfolio companies.

Michael Boggs

Managing Partner

Fred Lee

Managing Director

Zachary R. Scott

Managing Partner

Suchira Sharma

Associate

26 past transactions

Dren Bio

Series B in 2022
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.

Aspen Neuroscience

Series B in 2022
Aspen Neuroscience, Inc. is a private biotechnology company based in San Diego, California, focused on developing innovative therapies for neurological conditions, particularly Parkinson's disease. Established in 2018, the company utilizes induced pluripotent stem cells to create patient-specific restorative cell therapies. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version aimed at familial forms of the disease. Aspen Neuroscience combines genomic approaches with stem cell biology to advance its mission of modifying the course of Parkinson's disease through these novel therapeutic strategies.

IntelyCare

Series C in 2022
IntelyCare offers a digital workforce augmentation platform that combines a gig-model application with advanced data science to optimize staff resources and close the widening gap between workforce supply and demand. IntelyCare is revolutionizing the antiquated healthcare staffing market, filling nursing shifts at three times the industry average and giving post-acute facilities the tools to predict and manage staffing needs. The company’s engaging mobile app empowers nursing professionals with access to flexible, on-demand work opportunities, reducing burnout and attrition while increasing productivity.

Gravia

Series E in 2022
Gravie, Inc. operates a health insurance platform that facilitates the comparison and purchase of health insurance plans for individuals, families, and employers. Founded in 2013 and headquartered in Minneapolis, Minnesota, the company provides a comprehensive solution for managing health insurance expenses through its mobile application and website. Gravie allows users to shop for insurance options available on government-run exchanges and directly from insurance companies. The platform also offers tools for employers to design custom benefits plans using a defined contribution approach, enabling them to set a fixed budget for employee health benefits. Additionally, Gravie provides year-round support, financial analysis, and services such as Gravie Care, which assists individuals in managing their healthcare expenses effectively.

Endeavor BioMedicines

Series B in 2022
Endeavor BioMedicines is developing new treatments targeting the underlying causes of pulmonary fibrosis.

HotSpot Therapeutics

Series C in 2021
HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment. The company's platform helps to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspot structures, harnessing the power of data science in its multidisciplinary approach to drug discovery enabling patients to get treatment against several diseases.

Click Therapeutics

Series B in 2021
Click Therapeutics, Inc. specializes in the engineering, validation, development, and commercialization of digital therapeutic solutions aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012 and based in New York, the company offers innovative digital therapeutics for a range of conditions, including smoking cessation, major depressive disorder, schizophrenia, insomnia, and chronic pain. Its Digital Therapeutics™ are designed to function independently or alongside traditional biomedical treatments, utilizing the Clickometrics® adaptive data science platform to personalize user experiences and enhance engagement. Notably, Click's smoking cessation program has gained widespread access through various payers and providers, while its primary prescription program is advancing into a significant phase III clinical trial for major depressive disorder in adults.

SPR Therapeutics

Series D in 2021
SPR Therapeutics, LLC is a medical device company focused on developing and commercializing interventional pain management therapies. The company specializes in peripheral nerve stimulation (PNS) products, including its flagship Smartpatch system, which provides short-term pain relief following surgeries and for various types of pain such as neuropathic and musculoskeletal pain. Smartpatch is designed for minimally invasive use, allowing for up to 30 days of electrical stimulation to alleviate pain. Additionally, the company offers the Micropulse system for long-term therapy through an implantable PNS solution. SPR Therapeutics aims to provide a non-narcotic alternative to opioids and invasive procedures, emphasizing safety, effectiveness, and affordability in pain management. Founded in 2009 and headquartered in Cleveland, Ohio, the company also has facilities in the Carolinas and Minneapolis.

Genome Medical

Series C in 2021
Genome Medical, Inc. is a national telegenomics company that specializes in providing genetic consultation and medical consulting services. Incorporated in 2016 and based in South San Francisco, California, the company utilizes its Genome Care Delivery technology platform to deliver genetic solutions across various clinical areas, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacy. By leveraging a nationwide network of genetic specialists, Genome Medical offers expert virtual genetic care to individuals and families, enhancing their health and well-being. The company also assists healthcare providers and patients in navigating the expanding field of genetics, enabling them to interpret test results, assess disease risk, expedite diagnoses, make informed treatment choices, and reduce healthcare costs.

Gravia

Series D in 2021
Gravie, Inc. operates a health insurance platform that facilitates the comparison and purchase of health insurance plans for individuals, families, and employers. Founded in 2013 and headquartered in Minneapolis, Minnesota, the company provides a comprehensive solution for managing health insurance expenses through its mobile application and website. Gravie allows users to shop for insurance options available on government-run exchanges and directly from insurance companies. The platform also offers tools for employers to design custom benefits plans using a defined contribution approach, enabling them to set a fixed budget for employee health benefits. Additionally, Gravie provides year-round support, financial analysis, and services such as Gravie Care, which assists individuals in managing their healthcare expenses effectively.

Nuvolo

Series C in 2021
Nuvolo Technologies Corporation offers a cloud-based enterprise asset management platform built on the ServiceNow framework. Established in 2013 and headquartered in Paramus, New Jersey, with additional offices in London, Bulgaria, and India, Nuvolo specializes in life-cycle management solutions for assets in clinics, laboratories, facilities, and manufacturing sectors. The company provides a comprehensive suite of services that includes implementation, support, tracking, reporting, and analytics, aimed at enhancing the user experience for mobile and remote workforces. Known for its commitment to innovation and customer service, Nuvolo has formed strategic partnerships with major firms such as Atos, KPMG, and Unisys to further its mission of becoming a leader in cloud-based enterprise asset management.

SetPoint Medical

Venture Round in 2021
SetPoint Medical Corporation, a clinical-stage bioelectronic medicine company, develops implantable neuromodulation devices for treating patients with debilitating inflammatory diseases. SetPoint Medical Corporation was formerly known as Innovative Metabolics Inc. and changed its name to SetPoint Medical Corporation in July 2008. The company was incorporated in 2006 and is based in Valencia, California.

SomaLogic

Series A in 2020
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

NeuroPace

Private Equity Round in 2020
NeuroPace, Inc. specializes in the design, development, manufacturing, and marketing of implantable devices aimed at treating neurological disorders through responsive stimulation. The company's flagship product, the RNS System, is specifically designed for patients with medically refractory partial epilepsy. This system includes a small implantable neurostimulator that monitors brain activity and delivers electrical pulses to targeted areas to prevent seizures. The RNS System comprises various components, such as depth leads and cortical strip leads for implantation, along with external devices like a programmer that allows healthcare professionals to communicate with the neurostimulator. Founded in 1997, NeuroPace is headquartered in Mountain View, California.

MISSION Therapeutics

Venture Round in 2020
MISSION Therapeutics Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small-molecule drugs that selectively target deubiquitylating enzymes (DUBs). The company's pipeline includes promising candidates such as USP30, which is aimed at treating Parkinson's disease and cancer, and USP7, which is recognized as a significant target in oncology. In addition to these, MISSION Therapeutics has various DUB programs that address conditions in oncology, neurodegeneration, rare mitochondrial diseases, kidney disease, and inflammation. Founded in 2011, the company is actively engaged in advancing its innovative drug development platform, which capitalizes on the ubiquitin pathway to enhance protein homeostasis and offers potential therapeutic options in several challenging medical areas.

Genome Medical

Series B in 2020
Genome Medical, Inc. is a national telegenomics company that specializes in providing genetic consultation and medical consulting services. Incorporated in 2016 and based in South San Francisco, California, the company utilizes its Genome Care Delivery technology platform to deliver genetic solutions across various clinical areas, including cancer, cardiovascular health, reproductive health, pediatrics, and pharmacy. By leveraging a nationwide network of genetic specialists, Genome Medical offers expert virtual genetic care to individuals and families, enhancing their health and well-being. The company also assists healthcare providers and patients in navigating the expanding field of genetics, enabling them to interpret test results, assess disease risk, expedite diagnoses, make informed treatment choices, and reduce healthcare costs.

Evidation Health

Series D in 2020
Evidation Health is a provider of a health data analytics platform designed to collect and analyze continuous behavior data and healthcare information so as to create better health outcomes. Its platform turns raw, high-frequency everyday behavior data from sensors, devices, speech, video, and other sources into new knowledge about health and disease, that enable individuals and innovative companies to understand and influence the everyday behaviors. It was founded in 2012 and is headquartered in San Mateo, California.

Arterys

Series C in 2020
Arterys Inc. is a technology company specializing in medical imaging analytics, aiming to enhance patient care through innovative solutions. Founded in 2007 and headquartered in San Francisco, California, with additional offices in Calgary and Paris, Arterys offers a cloud-based, AI-powered platform that enables radiologists to visualize and quantify blood flow in the body. Its product lineup includes Cardio AI for cardiac imaging, Lung AI for lung analysis, Liver AI for liver diagnostics, and Chest/MSK AI for detecting various thoracic and musculoskeletal conditions. The platform is fully web-based and FDA-cleared, providing clinicians with tools for automatic and interactive reporting. Additionally, the Arterys PHI Service allows physicians to access patient data remotely, further supporting efficient medical practices.

Syapse

Series F in 2020
Syapse, Inc. is a company that specializes in precision medicine through its software platform, which integrates and analyzes clinical, molecular, treatment, and outcomes data. This platform supports data-driven decision-making for healthcare executives, care teams, and researchers involved in precision medicine programs. One of its key offerings is the Syapse Learning Health Network, a global data-sharing network focused on oncology, which leverages real-world data to enhance clinical decision-making. By connecting health systems, life sciences companies, and regulators, Syapse aims to accelerate the generation of real-world evidence to improve cancer patient outcomes. Founded in 2008 and headquartered in San Francisco, California, Syapse is committed to ensuring that all cancer patients receive high-quality care through improved precision medicine initiatives.

Singular Genomics

Venture Round in 2019
Singular Genomics is a venture capital-backed biotech company in La Jolla, California. It fosters a dynamic, fast-paced, results-oriented environment where they offer employees the opportunity to make a significant impact in a rapidly expanding company. Singular Genomics is inventing at the forefront of genomics, one of the world’s fastest-growing industries. The company is located in the center of the Biotech hub on the Torrey Mesa close to the Pacific Ocean and next door to prestigious institutions like the Salk Institute, Scripps, Sanford Burnham, and UCSD.

Providence Medical Technology

Venture Round in 2018
Providence Medical Technology is a privately-held medical device company focused on innovative solutions for cervical spinal conditions. The company has pioneered a proprietary approach to cervical fusion and has developed surgical instrumentation and implants that offer unique benefits to the $2 billion worldwide cervical spine market. The Providence family of products includes the DTRAX® Spinal Instrumentation System, CAVUX® intervertebral implants, and the ALLY® line of bone and facet screws. All products are shipped-sterile and single-use to maximize perioperative efficiency and ensure consistent quality and performance.

Vertos Medical

Venture Round in 2017
Vertos Medical is a healthcare company that offers medical devices used in the treatment of common spinal diseases. The company commercializes the percutaneous treatment for lumbar spinal stenosis (LSS). It also offers minimally invasive lumbar decompression devices for the treatment of various forms of LSS. The company offers its devices in the United States. Vertos Medical, Inc. was founded by Dr. Dave Solsberg and Dr. Don Schomer in 2005 and is headquartered in Aliso Viejo, California, USA.

ClearCorrect

Private Equity Round in 2016
ClearCorrect, LLC, founded in 2006 and based in Round Rock, Texas, specializes in the development and manufacturing of clear dental aligners designed to straighten teeth without the use of traditional metal braces. The company offers a series of custom, removable aligners that are prescribed and fitted by dental professionals, allowing for gradual teeth movement toward the desired alignment. ClearCorrect's approach emphasizes patient comfort and convenience, providing an effective solution for orthodontic treatment that is both affordable and compatible with dental practices. Since becoming a subsidiary of Straumann Holding AG in 2017, ClearCorrect continues to focus on innovative dental solutions that enhance patient care and satisfaction.

Bluesight

Series B in 2015
Bluesight is a software tool developed by Kit Check, Inc. that focuses on substance tracking and drug diversion detection within hospital pharmacies. This platform is part of a broader suite of cloud-based solutions designed to enhance the efficiency of pharmacy operations, including medication tracking and kit automation. Kit Check, Inc. utilizes Internet of Things (IoT) technology to significantly reduce kit replenishment time while increasing accuracy and minimizing errors. The company serves hospitals and pharmacies throughout the United States and Canada, tracking a substantial volume of medication, which contributes to improved supply chain management and operational safety. Founded in 2011 and based in Washington, D.C., Kit Check continues to innovate in the healthcare technology sector.

AcuFocus

Venture Round in 2014
AcuFocus, Inc. is an ophthalmic medical device company based in Irvine, California, specializing in small aperture technologies aimed at enhancing near vision. The company offers the KAMRA inlay, designed to assist presbyopic patients in restoring their near vision while preserving distance clarity. Additionally, AcuFocus provides the IC-8 IOL, a small aperture lens that accommodates a range of vision for cataract patients. The AcuTarget HD system serves as a diagnostic and surgical planning tool, aiding in the optimal treatment selection for various eye conditions, including LASIK and dry eye. AcuFocus markets its products through distribution partners across the Americas, Asia-Pacific, Europe, and the Middle East, thereby serving a global clientele of physicians and patients. Founded in 2001, AcuFocus continues to focus on advancing solutions for presbyopia and related vision issues.